Tina S. Nova, Ph.D., is General Manager, Decipher Urologic Cancers, at Veracyte. In this role, Dr. Nova oversees all business operations and financial results for Veracyte’s genomic tests in Urologic Cancers, which include the market-leading Decipher Prostate Genomic Classifier and the Decipher Bladder Genomic Test.

Dr. Nova is a life science industry veteran with extensive experience building and leading novel genomics-based businesses. She most recently served as President of Veracyte’s CLIA U.S. Business, before transitioning to her current role. Dr. Nova served as Chief Executive Officer of Decipher Biosciences prior to the company’s acquisition by Veracyte in March 2021.  Earlier in her career, she was President and Chief Executive Officer of Molecular Stethoscope, Inc., a molecular diagnostics company, and before that served as Senior Vice President and General Manager of Illumina’s Oncology business unit. From 2000 to 2014, Dr. Nova was Co-Founder, Director, President and Chief Executive Officer of Genoptix Medical Laboratory, which was purchased by Novartis Pharmaceuticals Corporation in 2011. She also held previous senior positions with Nanogen, Inc., Ligand Pharmaceuticals, Inc. and Hybritech, Inc. Dr. Nova currently serves on the board of directors of Exagen, Inc., and of Azenta Life Sciences. Prior to the acquisition of Decipher, Inc., she served on Veracyte’s board of directors.

 She holds a B.S. degree in Biological Sciences from the University of California, Irvine, and a Ph.D. in Biochemistry from the University of California, Riverside.